环丙沙星和去甲基万古霉素治疗耐甲氧西林金葡菌心内膜炎的实验研究

耐甲氧西林金葡菌(MRSA)是院外和院内感染的重要致病菌,近年来已引起国内外许多学者的关注。环丙沙星为一新型氟代喹喏酮衍生物,体外实验证实,该品对MRSA有抗菌活性。本文旨在运用MRSA细菌性心内膜炎动物模型,对国产环丙沙星和去甲基万古霉素进行体内比较性研究,对环丙沙星的药物疗效进行临床前评价,为今后该品用于临床提供理论和实验依据。研究结果表明,经药物治疗三天后,赘生物菌落数明显下降,与实验对照组有显著差别(P<0.01),而治疗组间无差别(P>0.05)。可以预测,环丙沙星可能成为替代去甲基万古霉素治疗MRSA感染的较好品种之一,有待于在治疗人体感染中证实。

STUDY OF CIPROFLOXACIN AND DEMETHYLYANCOMYCIN IN THE TREATMENT OF EXPERIMENTAL METHICILLINRESISTANCE STAPHYLOCOCCUS AUREUS ENDOCARDITIS

Methicillin-resistance Staphylococcus aureus (MRSA)is an important community and hospital acquired infectious phathogen. In recent years, the microorganism has been noted by many international and domestic experts. Ciprofloxacin, a flourinated 4-quinolone antibiotic, has been shown to have excellent result in vitro activity against MRSA. The purpose of this study is to compare the efficacy of ciprofloxacin with that of demethylvancomycin using the Rabbit model of MRSA endocarditis. Efficacy of pre-clinical therapeutic for ciprofloxacin has also been evaluated. Comparative studies of the efficacy of ciprofloxacin versus that of demethylvancomycin show that, after 3 days of therapy, bacterrial counts in vegetations reduced remarkably.Significant differences between the cip-rofloxacin-treated animals and the controls and between the demethylva-ncomycintreated animals and the controls in all cases were noted (p< 0.01). It is observed that no significant difference in bacterial counts between the ciprofloxacin and demethylvancomycin treatment groups. It is speculated that ciprofloxacin would be a useful alternative to demethyl vancomycin for treating MRSA infection. It would be confirmed for efficacy of ciprofloxacin to treat MRSA infection in human.